Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer. (2023)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ccell.2023.04.005
PubMed Identifier: 37116490
Publication URI: http://europepmc.org/abstract/MED/37116490
Type: Journal Article/Review
Volume: 41
Parent Publication: Cancer cell
Issue: 5
ISSN: 1535-6108